company background image
WVE logo

Wave Life Sciences NasdaqGM:WVE Stock Report

Last Price

US$14.04

Market Cap

US$2.3b

7D

-5.3%

1Y

123.2%

Updated

03 Dec, 2024

Data

Company Financials +

Wave Life Sciences Ltd.

NasdaqGM:WVE Stock Report

Market Cap: US$2.3b

WVE Stock Overview

A clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. More details

WVE fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Wave Life Sciences Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Wave Life Sciences
Historical stock prices
Current Share PriceUS$14.04
52 Week HighUS$16.74
52 Week LowUS$3.50
Beta-1.14
11 Month Change1.52%
3 Month Change174.22%
1 Year Change123.21%
33 Year Change283.61%
5 Year Change-60.01%
Change since IPO-12.25%

Recent News & Updates

US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results

Nov 15
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results

Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking

Nov 09
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking

Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst

Oct 16

Recent updates

US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results

Nov 15
US$22.20 - That's What Analysts Think Wave Life Sciences Ltd. (NASDAQ:WVE) Is Worth After These Results

Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking

Nov 09
Optimistic Investors Push Wave Life Sciences Ltd. (NASDAQ:WVE) Shares Up 95% But Growth Is Lacking

Wave Life Sciences: Positive WVE-006 Data For AATD Leads To 2025 Catalyst

Oct 16

There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump

Sep 25
There's Reason For Concern Over Wave Life Sciences Ltd.'s (NASDAQ:WVE) Massive 43% Price Jump

Wave Life Sciences: Spiking On Strong DMD Data, But Not Fully De-Risked Yet

Sep 24

Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher

Sep 08
Broker Revenue Forecasts For Wave Life Sciences Ltd. (NASDAQ:WVE) Are Surging Higher

We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Aug 05
We're Keeping An Eye On Wave Life Sciences' (NASDAQ:WVE) Cash Burn Rate

Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

Jun 25
Pinning Down Wave Life Sciences Ltd.'s (NASDAQ:WVE) P/S Is Difficult Right Now

We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Apr 09
We Think Wave Life Sciences (NASDAQ:WVE) Can Easily Afford To Drive Business Growth

Wave Life Sciences' Weighty Ambition: Carving Out Obesity Niche

Mar 09

Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

Mar 03
Wave Life Sciences Ltd.'s (NASDAQ:WVE) 30% Price Boost Is Out Of Tune With Revenues

We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Sep 13
We're Interested To See How Wave Life Sciences (NASDAQ:WVE) Uses Its Cash Hoard To Grow

Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

May 08
Wave Life Sciences Ltd. (NASDAQ:WVE) Analysts Just Cut Their EPS Forecasts Substantially

Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Mar 30
Here's Why Wave Life Sciences (NASDAQ:WVE) Must Use Its Cash Wisely

Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Jan 20
Are Investors Undervaluing Wave Life Sciences Ltd. (NASDAQ:WVE) By 47%?

Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Nov 11
Some Analysts Just Cut Their Wave Life Sciences Ltd. (NASDAQ:WVE) Estimates

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Aug 12
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Deliver On Growth Plans?

Wave Life Sciences Q2 2022 Earnings Preview

Aug 10

Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Apr 21
Will Wave Life Sciences (NASDAQ:WVE) Spend Its Cash Wisely?

Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Jan 11
Is Wave Life Sciences (NASDAQ:WVE) In A Good Position To Invest In Growth?

Shareholder Returns

WVEUS PharmaceuticalsUS Market
7D-5.3%0.8%0.4%
1Y123.2%12.1%32.3%

Return vs Industry: WVE exceeded the US Pharmaceuticals industry which returned 12.1% over the past year.

Return vs Market: WVE exceeded the US Market which returned 32.2% over the past year.

Price Volatility

Is WVE's price volatile compared to industry and market?
WVE volatility
WVE Average Weekly Movement27.5%
Pharmaceuticals Industry Average Movement10.1%
Market Average Movement6.3%
10% most volatile stocks in US Market16.3%
10% least volatile stocks in US Market3.1%

Stable Share Price: WVE's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: WVE's weekly volatility has increased from 17% to 28% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2012267Paul B. Bolnowww.wavelifesciences.com

Wave Life Sciences Ltd., a clinical-stage biotechnology company, designs, develops, and commercializes ribonucleic acid (RNA) medicines through PRISM, a discovery and drug development platform. The company’s RNA medicines platform, PRISM, combines multiple modalities, chemistry innovation, and deep insights into human genetics to deliver scientific breakthroughs that treat both rare and prevalent disorders. It is developing WVE-006, a RNA editing oligonucleotide for the treatment of alpha-1 antitrypsin deficiency; siRNA clinical candidate for the treatment of obesity and other metabolic disorders; WVE-N531, a exon skipping oligonucleotide for the treatment of duchenne muscular dystrophy; and WVE-003, an antisense silencing oligonucleotide for the treatment of Huntington’s disease (HD).

Wave Life Sciences Ltd. Fundamentals Summary

How do Wave Life Sciences's earnings and revenue compare to its market cap?
WVE fundamental statistics
Market capUS$2.33b
Earnings (TTM)-US$142.52m
Revenue (TTM)US$53.61m

39.9x

P/S Ratio

-15.0x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
WVE income statement (TTM)
RevenueUS$53.61m
Cost of RevenueUS$149.11m
Gross Profit-US$95.50m
Other ExpensesUS$47.02m
Earnings-US$142.52m

Last Reported Earnings

Sep 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.93
Gross Margin-178.14%
Net Profit Margin-265.84%
Debt/Equity Ratio0%

How did WVE perform over the long term?

See historical performance and comparison